Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data

References

• Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis 2008; 67: 37–42
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008; 47: 495–9
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 2784–92
   PubMed Web of Science ®Google Scholar
• Jonsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ 2008; 8(Suppl 2)S61–86
   PubMed Web of Science ®Google Scholar
• Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 347–56
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modelling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002; 46: 2310–19
   PubMed Web of Science ®Google Scholar
• Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. German Collaborative Arthritis Centres. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006; 65: 1175–83
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jonsson B. The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur J Health Econ 2008; 8(Suppl 2)95–106
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab [Remicade(R)] in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003; 42: 326–35
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005; 64: 1174–9
   PubMed Web of Science ®Google Scholar
• Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005; 64: 995–1002
   PubMed Web of Science ®Google Scholar
• Geborek P, Saxne T. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 1159–61
   PubMed Web of Science ®Google Scholar
• Kobelt G, Eberhardt K, Geborek P. TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004; 63: 4–10
   PubMed Web of Science ®Google Scholar
• Karlsson JA, Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008; 47: 507–13
   PubMed Web of Science ®Google Scholar
• The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. Centre for Health Economics, University of York, York 1995
   Google Scholar
• Jacobsson L, Lindroth Y, Marsal L, Tejler L. [The Malmo model for private and public rheumatological outpatient care. Cooperation makes it possible to introduce disease modifying treatment quickly] in Swedish. Lakartidningen 2001; 98: 4710–16
   PubMedGoogle Scholar
• Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1169–75
   PubMed Web of Science ®Google Scholar
• Jacobsson LT, Lindroth Y, Marsal L, Juran E, Bergstrom U, Kobelt G. Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden. Scand J Rheumatol 2007; 36: 179–83
   PubMed Web of Science ®Google Scholar
• Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002; 29: 62–7
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48: 54–8
   PubMed Web of Science ®Google Scholar
• Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 670–5
   PubMed Web of Science ®Google Scholar
• National Statistics Office. 2008. Available from: www.scb.se.
   Google Scholar
• Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000; 39: 122–32
   PubMed Web of Science ®Google Scholar
• FASS. Lakemedel i Sverige [Pharmaceutical lexicon]. Stockholm: Lakemedelsinformation AB, 2008.
   Google Scholar
• Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66: 1339–44
   PubMed Web of Science ®Google Scholar
• Kobelt G. Health economic issues in rheumatoid arthritis. Scand J Rheumatol 2006; 35: 415–25
   PubMed Web of Science ®Google Scholar
• Bansback N, Ara R, Karnon J, Anis A. Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health states. Pharmacoeconomics 2008; 26: 395–408
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007; 46: 1345–54
   PubMed Web of Science ®Google Scholar